about
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.Economics of treatments for non-small cell lung cancer.Economic evaluation of epilepsy in Kiremba (Burundi): a case-control study.Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study).Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III studyManagement of elderly patients.ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerCombinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe.BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerCost of lung cancer: a methodological review.Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home.The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.Biomarkers in lung oncology.Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy.[Costs, costs and more costs: which one should we use?].Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study.Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial.An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis.Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).Treatment of lung cancer: will financial issues become a criterion of choice?A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisMulticenter phase II trial of carboplatin/vinorelbine in elderly patients with advanced non-small-cell lung cancer efficacy and impact on quality of life: Groupe Francais de Pneumo-Cancerologie Study 9902.Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.
P50
Q27851712-25358197-B782-43D4-B8C5-3C8DC3726FCFQ30360938-05592A66-00E2-4176-A6DB-4982E74648E8Q34016351-15C9B44E-4B8F-4D1C-841D-70B60B31E460Q34320867-29E9315A-63AA-485A-8DA9-EA6CCE89C10AQ34346373-C9C511F3-01AD-4256-B5A8-D861CEF6FEE3Q34914499-C84FE0A4-AD8A-43FA-8093-A4C440B64C7EQ34996046-E24D0B31-9CCE-472E-977B-DC3BFB6D168DQ35200398-AB724CD6-CF45-4148-83CA-F58B1AA65E21Q35200573-1627B7C2-4901-450D-83C2-DEE7701EBD12Q35752978-00ACCF48-2810-483A-A054-C427E261D6F8Q36017990-66AB78A1-933D-4B93-B141-F8EA9216F97FQ36248579-C4E8461D-9045-4199-94AF-A26E81A0A4E4Q36350128-03E7CBF7-B6E6-479E-8B54-931B3A6E08FEQ36520579-557962C1-E76A-40BA-9444-5AD7E28E016AQ37371179-B3FC9FBD-3C17-494D-A821-6E330DB45893Q37381571-1A357BB9-6876-4670-B2A0-800A9CF451FCQ37752935-0E7FB3FE-3647-4DD9-BC45-01A6839CF481Q38407938-E222B6F1-D81C-432C-8303-1A92EF904740Q38447570-635D1CC2-D2B1-4BB8-A47F-7C7B184EEA8EQ38463493-F1FEB32A-368A-403B-BAE4-6D82E65CDD18Q38650079-98161BD2-53B0-4FE5-9A6C-E80821D9F8CDQ38720801-C91C28D1-538E-4EBA-89F8-F8A0B698BDF1Q39040330-B6671FC8-45AF-4511-A369-9BF8E68DFAFAQ39619779-BDA8E112-3E92-4484-BEEB-FF3CBF6E7F96Q39962529-384830C8-319B-4CCB-BCAF-509048C7D98CQ39980379-CE5D7E04-59A1-4C38-80C0-CE74D119150AQ40869644-42518476-D99D-4C45-9970-F1830468BDFAQ41116559-1B6E477A-0259-4729-BC60-54DD720FE251Q42860384-D56AEA99-304A-457C-90B6-A09E718CECD3Q42930906-ED5EF13B-41A0-4FB7-A82A-09A4CEC974A9Q42930907-B49F56F5-8D1C-4504-8A69-3B9728624AB3Q43132442-36598767-86BB-4D6A-978D-6D27A857EAE3Q43558104-96879B7A-27BF-464C-9CC0-AA33CC5634C1Q43700771-FCE31249-BB49-4237-8D26-CA4C13A101FFQ45031765-C9233EFF-0E04-451B-84C0-109513E641CAQ45829810-C275005B-54C0-46C0-BC84-32DBBC4CFCE8Q45833913-02972DBA-2A20-433F-BA9A-7C45D7D3CEBDQ46155722-6053D984-C403-4D0D-8F39-925807F88EECQ46716461-99AC194B-5DD1-4847-839C-C5FD857D2AFEQ47096671-3219C8D3-EBDD-4759-A36C-A9B9070E0B0F
P50
description
researcher ORCID ID = 0000-0002-5356-6070
@en
wetenschapper
@nl
name
Alain Vergnenegre
@ast
Alain Vergnenegre
@en
Alain Vergnenegre
@es
Alain Vergnenegre
@nl
type
label
Alain Vergnenegre
@ast
Alain Vergnenegre
@en
Alain Vergnenegre
@es
Alain Vergnenegre
@nl
prefLabel
Alain Vergnenegre
@ast
Alain Vergnenegre
@en
Alain Vergnenegre
@es
Alain Vergnenegre
@nl
P31
P496
0000-0002-5356-6070